Pharmacotherapy of non-small cell lung cancer: A short review

O. Balaji

Research output: Contribution to journalReview articlepeer-review


Lung cancer is a global health problem with non-small cell lung cancer (NSCLC) being the most common histopathological variant causing almost 28% deaths in the United States of America. Platinum compounds were the mainstay of treatment, and since past 10 years, various newer targeted therapies have come into play. Epidermal growth factor receptor and anaplastic lymphoma kinase mutations play a major role in the development of advanced disease. Hence, targeted therapies and immunotherapies will remain an integral part in the management of advanced disease. Hence, this review focuses on the newer drugs approved by Food and Drug Administration to treat NSCLC.

Original languageEnglish
Pages (from-to)7-10
Number of pages4
JournalAsian Journal of Pharmaceutical and Clinical Research
Issue number3
Publication statusPublished - 01-03-2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacotherapy of non-small cell lung cancer: A short review'. Together they form a unique fingerprint.

Cite this